Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis

JAMA Cardiology 2026 Open access

Read full text
Authors: Niekbachsh Mohammadnia, Linke Li, Daniel Ezzat, Zhi Yu, Vineet K. Raghu, Jennifer L. Halford, Niels P. Riksen, Prem Natarajan, Jan H. Cornel, Michael C. Honigberg, Saloua El Messaoudi
DOI: 10.1001/jamacardio.2026.1852
Cited by: 1
References: 32

Abstract

Importance: Clinical heterogeneity exists among individuals with elevated lipoprotein(a) [Lp(a)] levels. Prior studies suggest that low-grade inflammation may modify this risk, but results remain conflicting. Objective: To test the hypothesis that inflammatory biomarkers may modify Lp(a)-associated risk for coronary artery disease (CAD) and aortic valve stenosis (AS) in a primary prevention population. Design, Setting, and Participants: Recruitment occurred between March 2006 through October 2010 among a population-based cohort of UK adults. UK Biobank participants without prevalent CAD or AS who underwent plasma proteomic profiling at study entry were eligible for inclusion. Data were analyzed from June 2025 through April 2026. Exposures: Lp(a) levels (

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Atherosclerosis and Cardiovascular Diseases Adipokines Inflammation and Metabolic Diseases

Publication details

Journal / source
JAMA Cardiology
Publisher
American Medical Association (AMA)
Volume
11
Issue
8
Pages
727–727
Publication date
24 June 2026
Language
EN